May 17 |
AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion': Analyst
|
May 17 |
The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
|
May 17 |
Erasca restructures; Novartis moves to complete MorphoSys deal
|
May 17 |
BMS reports four-year data from psoriasis treatment extension trial
|
May 16 |
Walmart Earnings & the State of the Consumer
|
May 16 |
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
|
May 16 |
New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis
|
May 16 |
Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
|
May 16 |
FDA approves Bristol Myers Squibb’s Breyanzi for follicular lymphoma
|
May 16 |
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
|